Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany

Table 2

Patient demographics and baseline disease characteristics of the matched OCT examination subgroups.

	≤4 OCT matched subgroup, N = 411	≥8 OCT matched subgroup, N = 411	value
Gender (n (%))			0.3197
Male	173 (42.1%)	159 (38.7%)
Female	238 (57.9%)	252 (61.3%)
Missing	0	0
Age (years)			0.8678
n	411	411
Mean (SD)	77.5 (9.0)	77.4 (8.2)
Pretreatment status			0.0003
Treatment-naïve	331 (80.5%)	300 (73.0%)
Pretreated with anti-VEGF	51 (12.4%)	93 (22.6%)
Possibly pretreated	29 (7.1%)	18 (4.4%)
Treatment delay (days)			0.2940
n	385	402
Mean (SD)	12.8 (13.0)	11.9 (10.9)
Median	10	9
Min–Max	0–79	0–57
BCVA of study eye at baseline			1.0000
n	411	411
Mean (SD) ETDRS letters	53.7 (18.4)	53.7 (18.4)

Pretreatment status was categorized as treatment-naïve (no previous intravitreal anti-VEGF documented and ≤90 days between diagnosis and first injection within OCEAN), pretreated (received anti-VEGF more than 3 months before study entry), and possibly pretreated (all patients not meeting the treatment-naïve or pretreated criteria). BCVA: best-corrected visual acuity; ETDRS: Early Treatment for Diabetic Retinopathy Study; Max: maximum; Min: minimum; nAMD: neovascular age-related macular degeneration; OCT: optical coherence tomography; SD: standard deviation; VEGF: vascular endothelial growth factor.